Health Care · In Vitro & In Vivo Diagnostic Substances

IDXX Idexx Laboratories SEC Filings & Insider Trading Activity 2026

company
CIK 874716101 filings
Nasdaq 100
S&P 500

IDXX at a glance

Idexx Laboratories (IDXX, SEC CIK 874716) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Idexx Laboratories (IDXX) reported revenue of $4.3 billion (up 10.4% from FY2024) and net income of $1.1 billion. Diluted EPS was $13.08.
  • As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Idexx Laboratories (IDXX) shares worth $17.3 billion in 13F-HR filings.
  • In the last 90 days, IDXX insiders reported 0 open-market purchases ($0) and 22 open-market sales ($28.6M) on Form 4, a net sale of $28.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.3B
+10.4% vs prior year
Insiders · 90 days
0 buys · 22 sells
Net −$28.6M
13F holders
41 funds
$17.3B · −4 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Provider of veterinary diagnostics, software, services, and water testing solutions with recurring consumable sales and instrument placements
  • New product emphasis: Launch and sales growth of IDEXX inVue Dx Analyzer driving 51.8% increase in instrument revenue for Companion Animal Group
  • Strategic shift: Increased focus on expanding SaaS veterinary software services and diagnostic imaging systems, with 10.6% revenue growth in these areas
  • Quantitative highlight: Total company revenue $4.3B, up 10.4% YoY with organic revenue growth of 9.6%; operating income up 20.5% to $1.36B
  • Noteworthy fact: Significant reduction in general & administrative expenses due to settled $61.5M litigation accrual, boosting net operating income and margins

Risk Factors

  • Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales
  • Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts
  • Supply dependency on third-party suppliers in U.S., Europe, and Asia Pacific for key components and raw materials
  • Sales volatility risk from distributor inventory fluctuations affecting reported sales growth, with limited visibility in certain countries
  • No disclosed specific financial leverage or key-person risks detailed in the section provided

Management Discussion & Analysis

  • Revenue $3.52B, up 9% YoY from $3.23B in prior year driven by Companion Animal Group growth
  • Operating margin 25.3% vs 24.1% prior year reflecting scale and efficiency gains
  • Best segment Companion Animal Group revenue $2.75B, up 11% YoY; worst segment Water revenue $309M, down 4% YoY
  • Operating cash flow $850M; capital expenditures $120M; share repurchases $200M; dividends paid $75M
  • Management expects mid-single-digit revenue growth and stable operating margin in FY2027; risks include supply chain disruptions and regulatory impacts

AI summary of the IDXX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from 2025 Annual Report risk factors
  • Unknown or currently immaterial risks could materially adversely affect business, financial condition, or future results

Management Discussion & Analysis

  • Revenue $1.214B, up 9.9% YoY from $1.105B
  • Operating margin 33.1% vs 32.1%; gross margin 62.9% vs 61.8%
  • Best segment CAG: revenue $1.116B, up 10.2%; worst LPD: $34.8M, up 2.6%
  • Operating cash flow $1.063B, up from $826.0M; cash $197.5M vs $180.1M
  • 2026 capital expenditure plan approximately $160.0M; tariff, inflation, freight and supply-chain headwinds cited

AI summary of the IDXX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Full financial results available in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1,214M, up 10% organically, confirming broad-based demand and strong commercial execution
  • EPS $4.01, up 18% reported and 22% comparable, with operating margin expanding 100 basis points to 33.1%
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full earnings release furnished as Exhibit 99.1, containing the detailed operating and financial results

Item EX-99.1: Item EX-99.1

  • Q2 revenue $1,217M, up 10% reported and 9% organic, led by CAG Diagnostics recurring revenue growth of 11% reported
  • EPS $4.27, up 18% reported and 15% comparable, with operating margin expanding 140 basis points to 35.0%
Filed May 15, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All three Class II director nominees elected to terms expiring at the 2029 annual meeting
  • PwC appointment ratified with 67,630,771 votes for, confirming auditor continuity

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Board declassification approved, with annual director elections beginning at the 2029 annual meeting
  • Shareholders owning at least 25% continuously for one year gain special-meeting rights, subject to bylaw conditions

AI summaries of IDXX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IDXX

Don't miss the next IDXX filing

  • Alerts as it files. A push when IDXX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IDXX, by share count.
  • Ask anything. An AI agent that reads every IDXX filing and answers with sources.

IDXX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lane MichaelMNov 18, 2026-
Lane MichaelMNov 18, 2026$505.53
Lane MichaelMNov 18, 2026-
Lane MichaelMNov 18, 2026-
Lane MichaelMNov 18, 2026$544.08
Lane MichaelMNov 18, 2026$206.94
MAZELSKY JONATHAN JAYGNov 16, 2026-
FENNELL GEORGEMNov 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$3.9B$4.3B
Gross Profit-$2.4B$2.7B
Operating Income-$1.1B$1.4B
Net Income-$887.9M$1.1B
Gross Margin-61.0%61.8%
Op. Margin-29.0%31.6%
Net Margin-22.8%24.6%
Balance Sheet
Total Assets$3.3B$3.3B$3.4B
Equity$1.5B$1.6B$1.6B
ROE-55.7%66.0%
Per Share
EPS-$10.67$13.08
Cash Flow
Operating CF-$929.0M$1.2B
CapEx-$120.9M$124.7M

Source: XBRL data in Idexx Laboratories (IDXX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IDXX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IDXX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202641$17.33B
Q2 202645$18.14B
Q1 202643$19.38B
Q4 202542$24.05B
Q3 202543$22.61B
Q2 202541$17.82B
Q1 202537$9.66B
Q4 202435$8.23B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 327 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IDXX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 18, 2026--
4Nov 12, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
4Nov 3, 2026--
10-QNov 2, 2026Analysis
8-KNov 2, 2026Analysis-
4Sep 9, 2026--
4Aug 24, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
4Aug 3, 2026--
8-KMay 15, 2026Analysis
4May 14, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis

Related Health Care companies

All Health Care →

IDXX SEC filings: frequently asked questions

Are IDXX insiders buying or selling?

In the last 90 days, Idexx Laboratories (IDXX) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $28.6 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IDXX stock?

As of September 30, 2026, the largest Idexx Laboratories (IDXX) holders among the 13F filers tracked by SignalX were BlackRock ($4.2 billion), Vanguard Capital Management LLC ($2.7 billion), Vanguard Portfolio Management LLC ($2.1 billion), State Street Corp ($2.0 billion), Invesco Ltd ($1.8 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IDXX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Idexx Laboratories (IDXX) reported revenue of $4.3 billion (up 10.4% from FY2024) and net income of $1.1 billion. Diluted EPS was $13.08. The figures come from the XBRL data in the 10-K.

What are the main risks in IDXX's latest 10-K?

In the 10-K filed February 20, 2026, Idexx Laboratories (IDXX) flagged: Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales. Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts. (AI summary of the Risk Factors section.)

What did IDXX report in its latest 8-K?

Idexx Laboratories (IDXX) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results announced for quarter ended September 30, 2026.

What are the latest IDXX SEC filings?

Idexx Laboratories (IDXX) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 20, 2026.

What is IDXX's SEC CIK number?

Idexx Laboratories (IDXX)'s SEC Central Index Key (CIK) is 874716. EDGAR lists every IDXX filing under that number.

Ask anything about IDXX

The research agent reads IDXX's filings, financials, insider trades and 13F holders, then answers with sources.